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Ginny Russell* and Tamsin FordAbstract
In this journal, Holden, Jenkins-Jones, Poole, Morgan, Coghill and Currie , CAPMH 7:34, 2013, report on the prevalence
and financial costs of treating people with attention deficit hyperactivity disorder (ADHD) in the UK over the last ten
years. We commend the authors on their thorough cost analysis, and discuss differences in prevalence estimates of
diagnosed ADHD, that is the proportion of the child population with an ADHD diagnosis, which varies dramatically
between studies. We also discuss the reasons for this. Regional variation in application of diagnostic criteria and clinical
subjectivity are likely partial explanations.
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Holden, Jenkins-Jones, Poole, Morgan, Coghill and
Currie [1] perform a thorough analysis of the costs of
treating ADHD, and estimate that the added overall cost
to the UK healthcare system for each individual with an
ADHD diagnosis is approximately £860 p.a. (approx.
$1430 US). This is an interesting and welcome analysis, not
least because it uses the individual as the unit and therefore
includes all the resource costs of the associated behaviours
such as self-harm and co-morbid conditions such as autism
which frequently accompany the presentation of ADHD.
Previous cost analyses have estimated an overall cost of
ADHD to various national economies [2,3], and such
estimates are based on measured prevalence of ADHD. As
Holden and colleagues rightly point out, estimates of the
prevalence of diagnosed ADHD vary widely. The Holden
study used stringent criteria to detect new diagnoses of
ADHD from the UK Clinical Practice Database between
1998 and 2008 to provide health service relevant incidence
and prevalence figures, and a comparison with age and
gender matched controls from the same database to
estimate health services resource use. There are many
methodological issues that complicate the estimation of
prevalence and incidence of diagnosed ADHD. In this
article, we discuss differences in prevalence estimates of
diagnosed ADHD and the reasons for this.* Correspondence: g.russell@exeter.ac.uk
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Holden et al. report the UK prevalence of diagnosed
ADHD at 0.5% in 2009 for registered patients aged 6
to 17 years, which is a surprisingly low estimate in
comparison with the prevalence of 9.5% for parent-reported
diagnoses of ADHD among children aged 4-17 years from
USA’s Center for Disease Control (CDC) in 2007 [4], and
our own estimate of 1.4% using the same measure of
parent-reported diagnosis in the UK among children
age 7 also in 2007 [5]. Comparable figures have been
derived for diagnosed ADHD in Europe: for example, in
Denmark, the prevalence estimate of diagnosed ADHD,
calculated from combining records from psychiatric
registers in secondary care and methylphenidate use,
is that 1.4% of children have an ADHD diagnosis [6].
Diagnoses, of course, particularly child, psychiatric
diagnoses, are subject to the vagaries of fashion. Indeed,
ADHD has been described as the ‘diagnosis du jour’ by
some scholars [7]. A more valuable prevalence estimate is
that based on the prevalence of children suffering from
symptoms of ADHD at clinical levels in the population.
Such estimates are made by epidemiological studies
using validated ADHD rating scales, such as the Connors
Scale, or standardised diagnostic measures such as the
Development and Well Being Assessment (DAWBA).
Using the DAWBA, the actual prevalence of children with
symptoms of ADHD in the UK population (as opposed to
children with ADHD diagnosis), was estimated at 1.5% in
2004 [8].tral Ltd. This is an Open Access article distributed under the terms of the
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in the samples selected and measures used can make
comparisons between figures all but meaningless. Polanski
and colleagues, for example, reported prevalence estimates
that varied from 1.5% to 25%, from studies across the world
[9]. These differences are due, at least in part, to wide
differences in the way ADHD is rated and by whom.
Additionally, different prevalence estimates in diagnosed
ADHD may reflect differences in recognition rather than
true differences in levels of underlying impairment. DSM
criteria, most often used in the US, are less stringent than
the ICD-10 criteria that are more often applied in Europe,
which may go some way toward explaining higher rates of
ADHD reported in the USA [10].
There are on going debates about whether the prevalence
of ADHD really is lower in the UK than in the US [11].
Holden et al.’s findings do suggest that ADHD diagnosis is
less often used by doctors in the UK than in the USA, but
this question of recognition must be separated from
estimates of the number of children suffering from these
impairing symptoms in the population who may not have
been brought to the attention of health services. The
identification of ADHD has be shown to vary across
geographical region [12], and by ethnicity [13] and gender:
girls are less often recognised than boys, as Holden and
colleagues point out. Such differences, either cultural, in
terms of differences in diagnostic criteria, or arising
from the ‘subjectivity of clinicians’ to which the article
refers, render the question of whether ADHD is under or
over-diagnosed a red herring: the answer depends on
where you fix the cut-point for clinical ADHD, and
this itself is a moving target [14].
Conclusion
Perhaps the more pertinent question is not ‘what is the
prevalence of diagnosed ADHD’, but whether it is helpful
for children to be diagnosed, or for families to have their
child diagnosed with ADHD / receive treatment. Making
this call involves weighing up the costs versus the benefits
of diagnosis of ADHD for each individual child and
family. Certainly, for children who are severely impaired,
numerous studies show that a range of outcomes at
adolescence and adulthood are negatively affected. These
include lower academic attainment, fewer employment
prospects, and less chance of forming stable long term
relationships, as well as increased odds of ending up with
a criminal record [15-17]. There is good evidence that
treatment with methylphenidate and other anti-ADHD
drugs is effective in improving some of these outcomes
[18] and can also improve family functioning [19].
There is also evidence to suggest non-pharmacological
interventions for childhood ADHD are moderately
effective. The extra costs for healthcare services in the UK
of $1430 per child estimated by Holden and colleaguesmay seem high, but given the evidence, this may be
inexpensive compared with the long-term costs, both social
and economic, of not treating severely affected children.
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